Adventris Pharmaceuticals GTM brain

Adventris develops investigational cancer immunotherapies including an off-the-shelf vaccine approach targeting mutant KRAS.

category

Investigational cancer vaccines

market profile

  • text: Shared KRAS mutations are an attractive oncology vaccine target, but immune response does not establish clinical benefit.
  • text: Adventris has licensed vaccine technology linked to Johns Hopkins research; published human evidence should not be confused with approval of a commercial Adventris product.

personas

  • title: Oncology biopharma business development leader
    pains:
    • Needs differentiated immuno-oncology assets supported by credible translational data.
    • Must assess IP, clinical risk and partnership economics before licensing.
  • title: Academic cancer trial investigator
    pains:
    • Needs new approaches for patients at risk of KRAS-driven disease.
    • Must evaluate safety, trial eligibility and meaningful outcomes before proposing studies.
  • title: Oncology biotech investor
    pains:
    • Must separate early immune signals from evidence of patient benefit.
    • Needs clarity on manufacturing, financing and regulatory milestones.

icp

  • text: Biopharma companies with oncology immunotherapy portfolios and external development or licensing teams, a prospective partner segment inferred from the product stage.
  • text: Academic cancer centers with KRAS and early-phase immunotherapy trial expertise, especially pancreatic oncology programs.

message pillars

  • text: Lead with the company's immunotherapy mission.
  • text: Invite development partners to a conversation.
  • text: Frame the technology as oncology immunotherapy, not a marketed cure.

objections

  • objection: Has the vaccine shown clinical benefit?
    response: Distinguish early immune response findings from proven efficacy and request the candidate-specific trial plan and endpoints.
  • objection: How strong are rights to the underlying science?
    response: Review patent claims, university licenses and field-of-use rights in diligence.
  • objection: What indication comes first?
    response: Ask for the current program and regulatory plan because historical accounts describe different initial indications.

competitors

  • name: Elicio Therapeutics
    why: Develops an off-the-shelf KRAS-targeted vaccine candidate.
  • name: BioNTech
    why: Develops cancer vaccines, including programs in lung cancer.
  • name: Moderna
    why: Develops investigational cancer vaccines, including shared-antigen approaches.

influencers

  • name: Jen Herbach
    url: https://spokengoods.com/podcasts/6136331-the-social-radars/founder-mode-jen-herbach-founder-ceo-adventris-pharmaceuticals/
    why: Founder and CEO discussing the company's development strategy.

keywords

  • KRAS cancer vaccine
  • mutant KRAS immunotherapy
  • off the shelf cancer vaccine
  • pancreatic cancer vaccine trial
  • cancer vaccine licensing
  • shared neoantigen vaccine

voice

  • clinical and restrained
  • direct and partnership-oriented

signals

  • text: A pharmaceutical company seeks external cancer vaccine or KRAS immunotherapy assets.
  • text: A cancer center expands early-phase pancreatic cancer prevention and immunotherapy research.

pricing

model: unknown

motion

unknown

channels

  • scientific publications
  • research partnerships

confidence

low

Founders

  • name: Jen Herbach
    title: Founder
    role: Founder
    bio: Jen Herbach is the CEO of Adventris Pharmaceuticals. She has more than a decade of biotech industry experience bringing novel oncology drugs to market, across companies including Onyx/Amgen, InterMune/Genentech, Exelixis, and Amunix. She holds an MBA from Harvard Business School and a Masters from the University of Cambridge.
  • name: William Collis
    title: Founder
    role: Founder
    bio: William Collis is a serial entrepreneur with multiple exits, most recently the data platform Genji. His research has been published in Harvard Business review and featured as a TED talk with over 1.5M views. He holds an MBA from Harvard Business School where he was named a Baker Scholar. He is lifelong friends with his co-founders Jen Herbach and Mark Yarchoan, since meeting as roommates at Amherst College.
  • name: Mark Yarchoan
    title: Founder
    role: Founder
    bio: Mark Yarchoan, M.D, is an Associate Professor of Medical Oncology at Johns Hopkins. Dr. Yarchoan runs an NCI-funded laboratory focused on developing novel immunotherapies, with a focus on cancer vaccines. He has led multiple international clinical trials of immunotherapy agents including neoantigen-targeted cancer vaccines. Dr. Yarchoan has received multiple honors, including the ASCO Young Investigator Award and the ASCO Career Development Award.

Back to YC companies